Ann: A$18.7m Osteopore, NDCS and A*STAR project hits milestones, page-93

Would be nice to see another update from the Management team.

"Testing for osteogenic differentiation revealed enhanced osteogenic
differentiation capabilities.
The project is now set to advance to in vivo studies of biological models, to gauge
the efficacy of bone regeneration.
“While we continue to prioritise our objective of commercialising our current products, we are
looking forward to working on new technologies – such as the next-generation jaw implant –
which supports our long-term vision of becoming the global leader in regenerative medicine,”
said Dr Lim.
The global dental bone graft and membrane substitutes market was valued at USD$11.47
billion in 2023, with a projected value of USD$27.55 billion by 2030."